Developing Novel Cancer Drugs On A Budget With Iterion Therapeutics' Rahul Aras, Ph.D.
About this episode
This episode features an interview with Rahul Aras, Ph.D., discussing capital efficient drug development in oncology at Iterion Therapeutics.
We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech we speak with Rahul Aras, Ph.D., President and CEO at Iterion Therapeutics, about capital efficient drug development in oncology and progressing a novel therapeutic with relatively small funding amounts. Iterion is a clinical stage company developing cancer therapeutics targeting the Wnt/β-catenin pathway, a known signaling target in oncology, but one that has confounded drug development ...
More episodes of Business Of Biotech
- Implementing A New CEO Strategy With NervGen's Adam Rogers, M.D. And Rich Macary
- The Impact Of FDA Risk On Biotech Rewards With CFO And Board Director Allan Shaw
- Biosimilars And Complex Medicines For All With RNA Therapeutics' Sarfaraz Niazi, Ph.D.
- Radiotherapeutics For Neuroendocrine Tumors With Perspective Therapeutics' Thijs Spoor
- Investing In Early-Stage Oncology With Yosemite's Dan McHugh
- Commercializing CAR T Cell Therapy With Legend Biotech's Alan Bash
Explore listener stats, chart rankings, contacts and more on the Business Of Biotech podcast page.